GSK shares shorted by leading U.S. hedge fund, The Times reports

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

TipRanks

Sat, Feb 15, 2025, 11:15 AM 1 min read

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s stock for more than a decade, The Times’ Ben Martin reports. Citadel, the $65B American investment firm, has built a net short position equating to 0.51 percent of GSK’s issued share capital, according to filings with the Financial Conduct Authority, the City regulator. It is the first time since late 2013 that an investor has amassed a short in GSK that is large enough to reach the 0.5 percent threshold requiring a public notification to the City authority.

Discover the Best Stocks and Maximize Your Portfolio:

See what stocks are receiving strong buy ratings from top-rated analysts.
Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on GSK: